Table II. Identification of PAF and ox-GPCs in human skin following RT.
| Tumor Type | Treatment | PAF | PAcPC | BPAF | PBPC | GPAF | PHPC | AzPAF | PAzPC | OVPAF | ONPAF | POVPC | PONPC | Ca2+ Response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCC #1 | Pre-RT | 3216 | 83 | 53 | 48 | 170 | ND | 6615 | 28255 | 7 | 6 | 6 | 15 | 25% |
| RT (0.3 Gy) | 4583 | 242 | 79 | 163 | 482 | ND | 10345 | 50059 | 27 | 16 | 7 | 64 | 78% | |
| BCC #2 | Pre-RT | 2633 | 45 | 30 | 30 | 109 | ND | 3623 | 18631 | 3 | 8 | 6 | 27 | 30% |
| RT (0.3 Gy) | 5950 | 59 | 117 | 203 | 396 | 4 | 9713 | 39834 | 12 | 36 | 9 | 82 | 62% | |
| Bladder Ca | Pre-RT | 2504 | 140 | 36 | 35 | 98 | 1 | 2991 | 15623 | 10 | 9 | 3 | 27 | 8% |
| RT (0.7 Gy) | 7410 | 376 | 205 | 309 | 534 | 5 | 10240 | 43593 | 15 | 37 | 7 | 69 | 22% | |
| Pseudo- | Pre-RT | 23 | 72 | 15 | 23 | 2 | 7 | 424 | NM | 26 | 280 | NM | 1328 | 2% |
| lymphoma | RT (0.2 Gy) | 3086 | 1031 | 96 | 127 | 25 | 28 | 1663 | NM | 103 | 832 | NM | 4511 | 48% |
Values of PAF and other GPC are pg per 90% of lipid extracts from 2 mm punch biopsy specimen; Ca2+ response denotes % of peak Ca2+ mobilization response compared to 1 μM CPAF in FURA-2-loaded KBP cells from 5% of the biopsy specimen. The names of each ox-GPCs in this table are: PAF, platelet-activating factor; PAcPC, 1-palmitoyl-2-acetyl-GPC; BPAF, 1-O-hexadecyl-2-butanoyl-GPC; PBPC, 1-palmitoyl-2-butanoyl-GPC; GPAF, 1-O-hexadecyl-2-glutaroyl-GPC; PHPC, 1-palmitoyl-2-hexanoyl-GPC; AzPAF, 1-O-hexadecyl-2-azeleoyl-GPC; PAzPC, 1-palmitoyl-2- azeleoyl-GPC; OVPAF, 1-O-hexadecyl-2-(5)oxo-valeroyl-GPC; ONPAF, 1-O-hexadecyl-2-oxononanoyl-GPC; POVPC, 1-palmitoyl-2-(5)oxo-valeroyl-GPC; PONPC, 1-palmitoyl-2-oxononanoyl-GPC.